title: Response to Dai et al.
authors.affiliation: 1] Department of Gastroenterology, University Hospital of Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Sud, Le Kremlin Bicêtre, France [2] INSERM, UMRS 1018, Team 9, Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Institut Gustave Roussy, Villejuif, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Racine
authors.affiliation: INSERM, UMRS 1018, Team 9, Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Institut Gustave Roussy, Villejuif, France.
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Boutron-Ruault
authors.affiliation: 1] Department of Gastroenterology, University Hospital of Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Sud, Le Kremlin Bicêtre, France [2] INSERM, UMRS 1018, Team 9, Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Institut Gustave Roussy, Villejuif, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Carbonnel
mesh_terms: D003093:Colitis, Ulcerative / Q000139:chemically induced*; D003424:Crohn Disease / Q000139:chemically induced*; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects*; D008297:Male
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin